No Danger Of Cancer Through Gene Therapy Virus AAV-LPL S447X
In the fall of 2012, the European Medicines Agency approved the modified adeno-associated virus AAV-LPL S447X as the first ever gene therapy for clinical use in the Western world.
AAV-LPL S447X was developed for the treatment of a rare inherited metabolic disease called lipoprotein lipase deficiency which affects approximately 1-2 out of 1,000,000 people. Though incredibly rare, the disease causes severe, life-threatening inflammations of the pancreas. Afflicted individuals carry a defect in the gene coding for the lipoprotein lipase enzyme which is necessary for breakdown of fatty acids.…